Isoray
Medical Devices, 350 Hills Street, Richland, Washington, 99354, United States, 11-50 Employees
Phone Number: 15*********
Who is ISORAY
The introduction of Cesium-131 represents the culmination of decades of work and millions of dollars of investment. Top medical centers, hospitals and clinics across the United States are...
Read More
-
Headquarters: 350 Hills Street, Richland, Washington, 99354, United States
-
Date Founded: 1998
-
Employees: 11-50
-
Revenue: $25 Million to $50 Million
-
Active Tech Stack: See technologies
Industry: Medical Devices
SIC Code: 3841
Isoray Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Isoray
Answer: Isoray's headquarters are located at 350 Hills Street, Richland, Washington, 99354, United States
Answer: Isoray's phone number is 15*********
Answer: Isoray's official website is https://isoray.com
Answer: Isoray's revenue is $25 Million to $50 Million
Answer: Isoray's SIC: 3841
Answer: Isoray has 11-50 employees
Answer: Isoray is in Medical Devices
Answer: Isoray contact info: Phone number: 15********* Website: https://isoray.com
Answer: The introduction of Cesium-131 represents the culmination of decades of work and millions of dollars of investment. Top medical centers, hospitals and clinics across the United States are now offering this breakthrough treatment for cancer patients. The word brachytherapy derives from the Greek prefix brachy, meaning short or close, because the titanium capsules containing the radioisotope are implanted directly into the cancerous prostate gland. Treatment of cancer using low dose radiation or seed brachytherapy was pioneered in the 1960s as an effective alternative to radical prostatectomy. Pioneers in brachytherapy research initially theorized about the use of Cesium-131 in a titanium capsule, however scientific and economic limitations at the time prevented its development and Iodine-125 emerged as an alternative. Beginning in 1967, Iodine-125 became the first radioisotope manufactured in a titanium capsule, or seed. While its use continues to this day, many patients and doctors in recent years have chosen Palladium-103, a faster-acting, shorter half-life isotope than Iodine-125. In order to obtain the clinical benefits of Palladiums short half-life, patients and clinicians were forced to settle for lower energy or tissue penetrating power. A team of scientists continued to believe the physical characteristics of Cesium-131* could potentially provide superior clinical benefits for seed brachytherapy patients. The team developed the patented process for economically separating and purifying Cesium-131 and in 1998 Isoray was founded to manufacture and commercialize Cesium-131 brachytherapy seeds to treat cancers.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month